News
UK government to allocate £25m for women’s health hubs
The investment is hoped to improve access to women’s health services and ease the pressure on the NHS
The UK government has announced a £25m investment to develop new women’s health hubs, as part of the Women’s Health Strategy for England.
Women across England will benefit from “tailored healthcare and support” as well as improved access and quality of care for services for menstrual problems, contraception, pelvic pain and menopause care.
The investment over the next two years is hoped to accelerate the development of women’s health hubs and ease the pressure facing the NHS.
The government says hub models will be tailored to meet local women’s needs with a focus on delivering services that better fit around their lives.
Hubs aim to address fragmentation in provision, for example by providing management of contraception and heavy bleeding in one visit, or integrating cervical screening with other aspects of women’s health care.
At the moment, women often need to attend multiple appointments and go to different places to access these essential services.
“New funding of £25m for women’s health hubs mean more women can get the right support that works around their daily lives,” said Health and Social Care Secretary, Steve Barclay, in a statement.
Minister for Women’s Health, Maria Caulfield, said: “Better access to specialist services is key to tackling health inequalities. The £25m funding will create new women’s health hubs providing specialist care and advice to women across the country.
“We are making excellent headway to meet our commitments set out in England’s first ever Women’s Health Strategy, aiming to boost the health and wellbeing of women and girls.”
Early adopter women’s health hubs already exist in England, including in Liverpool and Manchester.
Other existing hubs make use of digital models to tackle inequalities in access to care. The City and Hackney women’s health hub organises virtual menopause engagement events and group consultations, with follow-up in a physical location hub where needed.
Professor Dame Lesley Regan, appointed as the Women’s Health Ambassador as part of the strategy, said: “As a practicing gynaecologist, I have first-hand experience of how important it is for women to have easy access to the right care when they need it.
“It is crucial that we provide them with the best information and support at each and every stage of their journey.
“Women’s health hubs offer us the opportunity to provide holistic care – including contraception, help with period problems, early pregnancy problems, pelvic pain, menopause and cancer screening,” she continued.
“Timely access to high quality services will help to build women’s confidence in the healthcare system.”
NHS chief executive, Amanda Pritchard, added: “For too long, too many women have felt that their pain has been ignored, misunderstood or downplayed when they approach health professionals for help.
“The NHS is continuing to find ways to ensure women’s health is prioritised, that more focus is placed on their needs, and that access to the care they need is as convenient as possible – whether that’s for menstrual problems, menopause or contraception.
“So it is fantastic that this new funding will be made available to support the NHS to expand these one stop shops across the country.
“They are already making a huge difference where they are up and running and will hopefully go a long way in improving the health and experiences of women.”
The announcement comes days after the government announced the appointment of a Department of Work and Pensions Menopause Employment Champion to support women in the workplace.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Fertility2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







Pingback: UK ‘leading the way’ in women’s health innovation, say experts - FemTech World